Axsome Therapeutics,Inc. (NASDAQ:AXSM) Files An 8-K Other Events

Axsome Therapeutics,Inc. (NASDAQ:AXSM) Files An 8-K Other Events

Story continues below

Item8.01.Other Events.

On January3, 2017, Axsome Therapeutics,Inc. (the Company) issued
a press release announcing that it had received, from the U.S.
Food and Drug Administration, clearance of its Investigational
New Drug Application for one of the Companys lead product
candidates, AXS-05, for the treatment of agitation in patients
with Alzheimers disease. Such clearance permits the Company to
proceed with its planned Phase 2/3 clinical trial of AXS-05 in
this indication. The Company anticipates commencing this trial in
the first half of 2017.

The full text of the press release is filed as Exhibit99.1 hereto
and is incorporated herein by reference.

Item 9.01. Financial Statements and
Exhibits.

(d) Exhibits.

Exhibit Number

Description

99.1

Press release dated January3, 2017.



About Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Axsome Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the management of central nervous system (CNS) disorders, including pain. It operates in the business of developing novel therapies for the management of CNS disorders segment. Its product candidate, AXS-02 (disodium zoledronate tetrahydrate), is an oral, targeted, non opioid therapeutic for chronic pain. It is developing AXS 02 for the treatment of pain in over three conditions, such as complex regional pain syndrome (CRPS); knee osteoarthritis (OA) associated with bone marrow lesions (BMLs), and chronic low back pain (CLBP), associated with type I, or mixed type I and type II Modic changes (MCs). Its product candidate, AXS 05, is a fixed dose combination of dextromethorphan (DM) and bupropion. It is developing AXS 05 for the treatment of over two conditions, such as treatment resistant depression (TRD), and agitation in patients with Alzheimer’s disease (AD).

Axsome Therapeutics, Inc. (NASDAQ:AXSM) Recent Trading Information

Axsome Therapeutics, Inc. (NASDAQ:AXSM) closed its last trading session down -0.10 at 6.25 with 14,248 shares trading hands.

An ad to help with our costs